- Heberprot-P clinical phase I
- Heberprot-P clinical phase II
- Heberprot-P clinical trial phase III
- Chronic Wounds with Emphasis in Diabetic Foot Ulcers
- Intralesional Human Recombinant Epidermal Growth Factor for the Treatment of Advanced Diabetic Foot Ulcer: From Proof of Concept to Confirmation of the Efficacy and Safety of the Procedure
- Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue Healing Agents: Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Progression
- Effect of human epidermal growth factor on the tumor cell line A431: in vivo analysis of tumor growth inhibition and gene expression
- Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
- Unexpected Traits In Diabetic Wound Healing. Emerging Role of Epigenetic Events: A comment
- Histological and Transcriptional Expression differences between Diabetic Foot and Pressure Ulcers
- Evaluación económica del tratamiento con Heberprot P® para las úlceras del pie diabético en el Centro de Atención al Diabético La Habana, 2012–2014
- Reporte de Casos(Argentina)
